Bristol Myers Squibb's admilparant treatment successfully met its primary endpoint in a Phase 3 trial for idiopathic pulmonary fibrosis.

Observed price moves

• CTNM-13.06%10 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.